Last reviewed · How we verify
PRI-002
At a glance
| Generic name | PRI-002 |
|---|---|
| Also known as | Contraloid |
| Sponsor | PRInnovation GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PHASE2)
- Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (PHASE1)
- MAD Phase I Study to Investigate Contraloid Acetate (PHASE1)
- SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRI-002 CI brief — competitive landscape report
- PRI-002 updates RSS · CI watch RSS
- PRInnovation GmbH portfolio CI